Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.72 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | TDP2 | O95551 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | NMT1 | P30419 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7858420 | 1.00 | LPAR2 (0.72) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL11137034 | 0.90 | LPAR2 (0.88) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL11133691 | 0.90 | LPAR2 (0.88) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL2574097 | 0.85 | NMT1 (0.69) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL2574096 | 0.85 | NMT1 (0.69) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL13381223 | 0.84 | LPAR2 (1.00) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL8353493 | 0.84 | ALDH1A1 (1.00) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL8353487 | 0.84 | ALDH1A1 (1.00) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL4738270 | 0.82 | MAPT (1.00) | LPAR2LPAR3ALDH1A1MAPTKMT2A | |
| SCHEMBL5177071 | 0.82 | MAPT (1.00) | LPAR2LPAR3ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0758314-B1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | VANGUARD MEDICA LTD (GB) | 1999-09-15 | — | — | EP | claimed |
| US-5877204-A | Compounds containing a michael-acceptor, especially maleimide or maleic acid derivatives, directly or indirectly linked to a chromophore and their use in long lasting sunscreen compositions | VANGUARD MEDICA LIMITED (GB) | 1999-03-02 | — | — | US | claimed |
| EP-0758314-A1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | Vanguard Medica Limited (GB) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030646-A1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | VANGUARD MEDICA LIMITED (GB) | 1995-11-16 | — | — | WO | claimed |
| US-9005670-B2 | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-06-06 | — | — | US | disclosed |
| EP-1156036-A2 | Compounds with electron donor and electron acceptor functionality | National Starch and Chemical Investment Holding Corporation (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6300456-B1 | Compounds with electron donor and electron acceptor functionality | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION | 2001-10-09 | — | — | US | disclosed |
| EP-0758314-B1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | VANGUARD MEDICA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5877204-A | Compounds containing a michael-acceptor, especially maleimide or maleic acid derivatives, directly or indirectly linked to a chromophore and their use in long lasting sunscreen compositions | VANGUARD MEDICA LIMITED (GB) | 1999-03-02 | — | — | US | disclosed |
| EP-0758314-A1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | Vanguard Medica Limited (GB) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030646-A1 | COMPOUNDS CONTAINING A MICHAEL-ACCEPTOR, ESPECIALLY MALEIMIDE OR MALEIC ACID DERIVATIVES, DIRECTLY OR INDIRECTLY LINKED TO A CHROMOPHORE AND THEIR USE IN LONG LASTING SUNSCREEN COMPOSITIONS | VANGUARD MEDICA LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| US-4978607-A | CONTAINING GELATIN, MODIFIED WITH MONOFUNCTIONAL ACID DERIVATIVE, AND HARDENER, A CARBAMOYL PYRIDINIUM SALT; WITHOUT RETICULATED GRAIN | AGFA-GEVAERT AKTIENGESSELLSCHAFT (DE) | 1990-12-18 | — | — | US | disclosed |
| EP-0080451-B1 | METHOD AND COMPOSITION FOR DIENE RUBBER TREATMENT | MONSANTO COMPANY (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4528020-A | Urease inhibited urea based fertilizer compositions | ALLIED CORPORATION (US) | 1985-07-09 | — | — | US | disclosed |
| US-4433114-A | SULFUR OR ORGANOSULFUR COMPOUNDS, MALEAMIC ACID OR DERIVATIVES, TACKINESS, GREEN STRENGTH | MONSANTO COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0080451-A1 | Method and composition for diene rubber treatment | MONSANTO COMPANY (US) | 1983-06-01 | — | — | EP | disclosed |
| US-4320173-A | REINFORCEMENT AND ADHESIVES FOR VULCANIZED PRODUCTS | MONSANTO COMPANY (US) | 1982-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142887-A1 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES | EP300, HDAC1, KAT2A | LPAR2 1718/4885LPAR3 1293/4885ALDH1A1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.